Once-daily oral elinzanetant was associated with significantly reduced frequency of moderate to severe menopausal vasomotor symptoms compared with placebo, according to topline results from the ...

The FDA has extended the review period for elinzanetant for the treatment of moderate to severe vasomotor symptoms due to menopause.

Elinzanetant significantly reduced vasomotor symptoms (VMS), also known as hot flashes, associated with menopause overall and across a range of body mass index (BMI) and smoking history subgroups ...

Elinzanetant may address moderate to severe VMS by modulating a group of estrogen sensitive neurons in the hypothalamus region of the brain (the KNDy neurons) which, with the decrease of estrogen ...

Elinzanetant, the first dual neurokinin-1,3 (NK-1,3) receptor antagonist, modulates the KNDy neurons, a group of estrogen sensitive neurons in the hypothalamus region of the brain.

Elinzanetant statistically significantly reduced the frequency of moderate to severe vasomotor symptoms from baseline to week 4 and 12 vs placebo. Topline results were announced from a phase 3 ...

Elinzanetant was associated with fewer and less severe menopausal vasomotor symptoms over 12 weeks. The neurokinin-1,3 receptor antagonist was associated with improved sleep and quality of life vs ...

Elinzanetant is a first dual neurokinin-1,3 (NK-1,3) receptor antagonist, in late-stage clinical development for the non-hormonal treatment of moderate to severe VMS associated with menopause ...

Elinzanetant significantly reduced the frequency and severity of vasomotor symptoms in menopausal women by week 12. The drug also improved sleep disturbances and menopause-related quality of life ...

Elinzanetant is already being tested in the OASIS trials for VMS associated with menopause – an indication in which Bayer is in a head-to-head race with Astellas and its fezolinetant drug ...

The drug, deemed elinzanetant, can help reduced hot flashes and improve sleep for women experiencing menopause. Bayer has started trials on a new pill that could alleviate the struggles women face ...